Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ivana Tosevski"'
Autor:
Fei Hua, Swethajit Biswas, Melissa Vrohlings, Stephanie Jungmichel, Ivana Tosevski, Nadia Sanchez, Leonardo Borras, Drew Marquis, Scott Gruver
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3f8109cf554b40fbbbaf4720bb574f8a
Autor:
Elizabeth Ross, Swethajit Biswas, Gilberto Lopes, Melissa Vrohlings, Stephanie Jungmichel, Ivana Tosevski, Alessio Vantellini, Philip Knobel, Nadia Sanchez, Marian Van Kerckhoven, Giorgia Giacomazzi, Maria Liivrand, Reija Hieta, Nicholas Dupuis, Dieter Rondas, Pamela Swatkowski, Daniel Lenherr-Frey, Leonardo Borras
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e3cdbfe702454cfdae5aa7d9cfa13453
Autor:
Hong Ji, Clara Domke, Julia M. Martinez-Gomez, Sarah Jetzer, Kyriaki Ioannou, Philippe Legenne, Ivana Tosevski, Sophie Barsin, Mariam Gachechiladze, Nicolo Rigamonti, Simone Ragusa, Tamara Lekishvili, Rupert Kenefeck, Vladimir Kirkin, Joanna Roquette, Mitch Levesque, Karolin Rommel, Ana Florescu, Eliane Müller, Anne Goubier
Publikováno v:
Cancer Research. 81:1733-1733
Therapeutic agonists targeting CD40 have shown encouraging signs of anti-tumor efficacy in patients. Despite their initial promise however, optimal dosing of systemically active agents has been limited by toxicity and their full therapeutic potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66f1f710b47511b8fc99987423ea61cd
https://doi.org/10.1158/1538-7445.am2021-1733
https://doi.org/10.1158/1538-7445.am2021-1733
Autor:
Roham Parsa, Tobias Suter, Robert A. Harris, Ingrid Kockum, Jan Beckervordersandforth, Ursula Malipiero, Harald Lund, Lars Alfredsson, Andreas Warnecke, Marco Prinz, Adriano Fontana, Alexandra Gyllenberg, Doron Merkler, Xing-Mei Zhang, Tomas Olsson, Ivana Tosevski, Jan Hillert, Tojo James
Publikováno v:
Glia. 64:1925-1937
Intracerebral levels of Transforming Growth Factor beta (TGFβ) rise rapidly during the onset of experimental autoimmune encephalomyelitis (EAE), a mouse model of Multiple Sclerosis (MS). We addressed the role of TGFβ responsiveness in EAE by target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6546697471ff875b806b5096d05ed21d
https://doi.org/10.1002/glia.23033
https://doi.org/10.1002/glia.23033
Autor:
Laurent Juglair, Patricia Schildknecht, Ivana Tosevski, Michael T. Stumpp, Keith M. Dawson, Alexander Link, Camila de Almeida, Jörg Herbst, Elmar vom Baur, Niina Veitonmäki, Christof Zitt, Victor Levitsky, Joanna Robinson, Hong Ji, Guy Lemaillet, Heidi Poulet, Rik de Greef, Christian Reichen
Publikováno v:
Cancer Research. 80:2273-2273
Following the clinical success of checkpoint inhibitors, cancer immunotherapy is rapidly expanding into combination treatments to enhance response rates and duration. Engagement of co-stimulatory molecules from the tumor necrosis factor receptor (TNF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f2cd0aa1c4e9b1231b341f2f3a67f75
https://doi.org/10.1158/1538-7445.am2020-2273
https://doi.org/10.1158/1538-7445.am2020-2273
Autor:
Alexander Link, Mirela Matzner, Guy Lemaillet, Ralph Bessey, Elmar vom Baur, Christian Reichen, Julia Hepp, Patricia Schildknecht, Keith M. Dawson, Hong Ji, Alexander Titz, Joanna Taylor, Dan Snell, Laurent Juglair, Michael T. Stumpp, Ivana Tosevski, Victor Levitsky, Joerg Herbst, Christof Zitt, Andreas Harstrick
Publikováno v:
Cancer Research. 78:3752-3752
Agonistic antibodies against the T cell costimulatory receptor 4-1BB (CD137) have proved to be very efficacious anti-tumor agents in preclinical animal models. However, clinical development of 4-1BB agonistic antibodies has met with limited success t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75698e4a457b62a51468402813418ca6
https://doi.org/10.1158/1538-7445.am2018-3752
https://doi.org/10.1158/1538-7445.am2018-3752
Autor:
Ralph Bessey, Michael T. Stumpp, Alexander Titz, Victor Levitsky, Clara Metz, Ulrike Fiedler, Ivana Tosevski, Simon Fontaine, Alexander Link, Keith M. Dawson, Christof Zitt, Dan Snell, Christian Reichen, Daniel Steiner, Patricia Schildknecht, Julia Hepp, Zita Arany, Laurent Juglair, Yvonne Kaufmann
Publikováno v:
Journal of Clinical Oncology. 35:e14626-e14626
e14626 Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to activation of T-cells. Urelumab is currently in Phase 2 clinical development and has been reported to cause significant h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::753352c27a6e4c54f116a1bc83cc02b9
https://doi.org/10.1200/jco.2017.35.15_suppl.e14626
https://doi.org/10.1200/jco.2017.35.15_suppl.e14626